心血管健康的心外影像生物标志物:综合综述
本综述汇总了心外影像生物标志物与心血管健康的关系,涵盖肝脏脂肪变性、肾脏指标、胰腺体积、肺气肿、脑小血管病、异位脂肪与肌少症、乳腺动脉钙化及骨密度等,这些标志物可在常规非心脏影像中机会性评估,改善风险分层且不增加额外费用或辐射。未来需标准化、外部验证并整合入风险预测模型。
要点
- 常规非心脏影像可机会性评估肝、肾、胰、肺、脑、脂肪、肌肉、血管、乳腺和骨骼的心血管风险标志物。
- MRI、CT和超声检出的非酒精性脂肪性肝病独立预测主要不良心血管事件。
- 乳腺动脉钙化和低骨密度等心外血管与骨骼标志物与心血管发病率和死亡率相关。
核心结论
- 心外影像生物标志物可改善风险分层,并在不增加费用或辐射的情况下实现筛查。
- 未来优先事项包括标准化、外部验证和整合入风险预测模型,以推进精准心血管医学。
研究设计与样本
- 综述类文章,检索范围与纳入文献原文未报告。
关键影像表现/征象
- 非酒精性脂肪性肝病可在MRI、CT和超声上检出,独立预测主要不良心血管事件。
- 慢性肾脏病相关标志物包括肾脏大小、血管钙化和肾阻力指数,与不良结局相关。
- 胰腺体积减小与心血管疾病相关。
- CT定量的肺气肿和肺过度充气与冠状动脉疾病和心血管死亡相关。
- 脑小血管病标志物如白质高信号和静息性脑梗死与心血管事件相关。
诊断标准与关键数值
- 原文未报告敏感度、特异度、AUC、阈值或分级标准。
临床应用与阅片要点
- 常规非心脏影像可机会性评估心外影像生物标志物,以补充心血管风险分层。
- CT、MRI和超声定量的异位脂肪和肌少症可提供超越体重指数的预后价值。
- 心外血管和骨骼标志物如乳腺动脉钙化和低骨密度与心血管发病率和死亡率相关。
- 原文未据此给出推荐。
局限性
- 未来需标准化、外部验证并整合入风险预测模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Cardiovascular disease (CVD) is the leading global cause of morbidity and mortality. Beyond clinical risk factors and cardiac imaging, extracardiac imaging biomarkers provide complementary insight into cardiometabolic health. Routine non-cardiac imaging often depicts the liver, kidneys, pancreas, lung, brain, adipose tissue, muscle, vasculature, breast, and bone, enabling opportunistic risk assessment. Non-alcoholic fatty liver disease (NAFLD), detectable on MRI, CT, and ultrasound, independently predicts major adverse cardiovascular events (MACE). Chronic kidney disease-related markers including kidney size, vascular calcification, and renal resistive index also correlate with adverse outcomes. Reduced pancreas volume is similarly associated with cardiovascular disease. CT-quantified emphysema and lung hyperinflation are associated with coronary artery disease and cardiovascular mortality. Cerebral small vessel disease markers, such as white matter hyperintensities and silent brain infarcts, demonstrate associations with cardiovascular events. Ectopic adiposity and sarcopenia quantified by CT, MRI, and ultrasound add prognostic value beyond body mass index. Extracardiac vascular and skeletal biomarkers, such as breast arterial calcification and low bone mineral density, further associate with cardiovascular morbidity and mortality. Collectively, these markers improve risk stratification and enable screening without added cost or radiation. Future priorities include standardization, external validation, and integration into risk prediction models to advance precision cardiovascular medicine.
引用
- Ahn WJ, Choi IY, Shim E, et al. Extracardiac imaging biomarkers of cardiovascular health: a comprehensive review. Br J Radiol. 2026. PMID: 41527261. doi:10.1093/bjr/tqag006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。